Table 7.
Missed interventions for prevention and control of NCDs in Iran
| Objective | Missed interventions | Type of intervention |
|---|---|---|
| 1 | 1.3 Strengthen international cooperation for resource mobilization, capacity-building, health workforce training and exchange of information on lessons learned and best practices | Overarching/enabling policy interventions. |
| 2 | 2.2 Assess national capacity for prevention and control of NCDs | |
| 4 | 4.2 Explore viable health financing mechanisms and innovative economic tools supported by evidence | |
| 4 | 4.7 Develop and implement a palliative care policy, including access to opioids analgesics for pain relief, together with training for health workers | |
| 3 | 3.38 Limiting portion and package size to reduce energy intake and the risk of overweight/obesity | Other recommended interventions from WHO guidance (cost-effective analysis not available). |
| 3 | 3.45 Ensure that macro-level urban design incorporates the core elements of residential density, connected street networks that include sidewalks, easy access to a diversity of destinations and access to public transport | |
| 4 | 4.16 Anticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation | |
| 4 | 4.31 Oral cancer screening in high-risk groups (for example, tobacco users, betel-nut chewers) linked with timely treatment | |
| 4 | 4.10 Treatment of new cases of acute myocardial infarction** with either: acetylsalicylic acid, or acetylsalicylic acid and clopidogrel, or thrombolysis, or primary percutaneous coronary interventions (PCI) | Effective interventions with cost-effectiveness analysis >I$ 100 per DALY averted in LMICs. |
| 4 | 4.12 Primary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level | |
| 4 | 4.13 Secondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin | |
| 4 | 4.26 Vaccination against human papillomavirus (2 doses) of 9–13-year-old girls | ‘Best buys’: Effective interventions with cost-effectiveness analysis = I$ 100 per DALY averted in LMICs. |